Carbocyclic thromboxane A2 (CTA2) is a stable analog of TXA2. CTA2 is a potent coronary vasoconstrictor and is effective at concentrations as low as 1 nM in cat coronary arteries. Unlike other vascular TP receptor agonists, CTA2 is a potent inhibitor of prostanoid-induced platelet aggregation. It inhibits arachidonic acid-induced aggregation with an IC50 value of 4-5 μM. CTA2 also exhibits selective and dose-dependent inhibition of TXB2 synthesis in rabbit platelets at concentrations between 1 and 100 μM.
Carbocyclic Thromboxane A2 is a stable analog of TXA2 which inhibits thromboxane-mediated vasoconstriction platelet aggregation. Also, it converts the thromboxane synthase (TXAS) heme cofactor to its 5-coordinate.
